Kala Pharmaceuticals Earning Date (KALA)

USA |NASDAQ |USD

KALA Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $-0.48
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $3.05M

Kala Pharmaceuticals's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

KALA Earnings Date & History Chart

KALA Earnings & Revenue Forecast

KALA Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 3 $-1.43 $-1.76 $-1.06

KALA Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 1 $-1.35 $-1.29 $-1.27

KALA Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 6 $27.27M $18.03M $40.00M

KALA Earnings Date & Revenue History

KALA Earnings History

|
Show More
Show More

KALA Revenue History

|
Show More
Show More

Kala Pharmaceuticals Next Earnings Date & Report

KALA Next Earnings Date & Report Preview: Jun 2022 (FQ)

KALA's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Kala Pharmaceuticals Previous Earnings Dates & Reports

KALA Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Kala Pharmaceuticals's previous earnings date was May 6, 2022 for its fiscal quarter ended Mar 31, 2022.

KALA Previous Earnings Date & Report Recap: Dec 2021 (FY)

Kala Pharmaceuticals's previous annual earnings date was Mar 29, 2022 for its fiscal year ended Dec 31, 2021.

KALA's earnings per share (EPS) was $-2.08, missing the consensus analysts forecast of $-1.90 by 9.57% , and lower than the previous year's EPS (Dec 2020) by 3.57%.

Revenues were $11.24M, worse than the forecast of $12.58M by -10.65%, and up by 76.67% from previous year's revenue.

The company reported a net income of $-142.60M.

Kala Pharmaceuticals reported a free cash flow of $-109.12M for its fiscal year, compared to $-92.64M a year ago.

The company ended the fiscal year with $80.19M in total debt, an increase of 8.70% compared to the previous year.